ArticleCancer medicine2026
The Effects of Bone-Remodeling Therapy on Survival, Pain, and Skeletal Related Events in the Setting of Renal Cell Carcinoma With Bone Metastases: A Multicenter Investigation From a Large Global Health Research Network (TriNetX).
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRenal cell carcinoma (RCC) is the most common renal malignancy-bone metastases (BM) are indicative of aggressive disease with a poor prognosis. We aim to evaluate the overall mortality of patients with RCC with and without BM, and to elucidate the effects of bone-remodeling therapy on mortality, incidence of skeletal-related events, and opioid usage patterns in patients with BM.
methodsA retrospective cohort study was conducted using TriNetX, a large, collaborative network sourced from electronic medical records of over 110 million patients from over 100 healthcare organizations. All adult patients with RCC and RCC with BM were queried.
resultsThere were 139,859 patients diagnosed with RCC, of which 9021 had RCC with bone metastases (BM). Among these, 999 patients received only bisphosphonates (BPs), 973 received only RANK ligand inhibitors (RANKLi), and 119 patients initially received BPs before switching to RANKLi. Presence of BM results in a ~2.5-fold increase in 5-year mortality rate (p < 0.0001) and a statistically significant increase in all SREs compared to those without BM. Patients receiving bisphosphonates had significantly higher rates of opioid use (p < 0.001) and comparable rates of chronic pain diagnoses to the overall BM group (p = 0.9217). In contrast, patients receiving RANKLi had a statistically significant reduction in opioid use (p < 0.001) and hypocalcemia (p < 0.001) compared to those on BPs, and an improved 5-year survival rate (p < 0.0001) and median survival (p < 0.0001) relative to the overall BM cohort.
conclusionPatients receiving RANKLi have significantly improved survival, reduced opioid use and lower rates of SREs. Patients with RCC and BMs experienced significantly worse outcomes compared to those without BM. Surprisingly, among RCC patients with BMs, those treated with BPs only experienced even poorer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.